☆ 3.8 Article

Humoral Responses in the Omicron Era Following 3-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients

TRANSPLANTATION DIRECT (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Surgery

SARS-CoV-2 antibody testing for transplant recipients: A tool to personalize protection versus COVID-19

William A. Werbel et al.

Summary: Anti-spike antibody testing is important for assessing SARS-CoV-2 vaccine response in solid organ transplant recipients. It is recommended to test all recipients for anti-spike antibodies after vaccination and personalize efforts to improve protection against COVID-19 based on the results.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Surgery

Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients

Nassim Kamar et al.

Summary: The immunogenicity of the SARS-CoV-2 vaccine was enhanced by a third dose. A retrospective study on solid organ transplant patients found that two-thirds of them developed anti-SARS-CoV-2 antibodies after three doses, but one-third remained weak or non-protected. Antibody concentrations and protection levels decreased between 1 and 3 months after vaccination.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Surgery

A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients

Andrew H. Karaba et al.

Summary: Vaccine-induced antibody responses are weaker in solid organ transplant recipients (SOTRs), and breakthrough infections are more common. Additional vaccine doses increase antibody levels in some SOTRs, but the neutralization capacity is still significantly lower than in healthy individuals.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Medicine, General & Internal

Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine Secondary Analysis of a Randomized Trial

Deepali Kumar et al.

Summary: This study assessed neutralizing antibody responses against SARS-CoV-2 variants in transplant recipients after receiving a third dose of mRNA vaccine. The results showed that the third dose of vaccine could enhance the neutralizing antibody response against variant viruses.

ANNALS OF INTERNAL MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series

Sophie Caillard et al.

ANNALS OF INTERNAL MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis

Kevin Yau et al.

Summary: In patients undergoing hemodialysis, mRNA-1273 elicited a stronger humoral response than BNT162b2. A third dose is recommended for patients who received BNT162b2 due to rapid decline in immunogenicity at 12 weeks.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2022)

Add to Collection

Article Urology & Nephrology

Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination

Louise Benning et al.

Summary: The antibody response after SARS-CoV-2 vaccination is impaired in kidney transplant recipients, especially against emerging variants like B.1.617.2 (d). Immunosuppressed patients show lower seroconversion rates and reduced neutralizing ability against different variants compared to healthy controls, indicating limited protection in the face of new strains.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Add to Collection

Article Surgery

SARS-COV-2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications

Gianluca Russo et al.

Summary: Solid organ transplant patients are at higher risk for poor COVID-19-related outcomes and have been prioritized for vaccination. A study in Italy assessed the safety and efficacy of the BNT162b2 mRNA vaccine in 82 kidney transplant patients, finding a 52.4% seroprevalence after 43 days post-vaccination with no impact on rejection or graft function. Age over 60 and use of anti-metabolites were associated with lack of seroconversion following vaccination. Further large studies are needed to determine the best vaccination strategy for transplanted patients.

CLINICAL TRANSPLANTATION (2022)

Add to Collection

Article Multidisciplinary Sciences

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Elisabetta Cameroni et al.

Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Yunlong Cao et al.

Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.

NATURE (2022)

Add to Collection

Article Immunology

Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses

Victoria G. Hall et al.

Summary: Delayed dosing intervals can enhance immune response to COVID-19 vaccination, including virus neutralization against wild-type and variant viruses. This finding has significant implications for the global implementation of vaccines.

NATURE IMMUNOLOGY (2022)

Add to Collection

Article Transplantation

mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?

Veerle P. W. M. Wijtvliet et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)

Add to Collection

Letter Medicine, General & Internal

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

Ital Nemet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Plasma Neutralization of the SARS-CoV-2 Omicron Variant

Fabian Schmidt et al.

Summary: Neutralization assays showed much lower omicron neutralization compared to Wuhan-hu-1 after two doses of mRNA vaccine, but individuals who received a booster vaccine or were vaccinated after recovering from Covid-19 exhibited high levels of omicron neutralization.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Peter B. Gilbert et al.

Summary: In the COVE phase 3 clinical trial, neutralizing and binding antibodies were measured in vaccine recipients to determine their correlation with COVID-19 risk and vaccine efficacy. The results showed that these immune markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Postvaccination neutralization titers of 10, 100, and 1000 correlated with estimated vaccine efficacies of 78%, 91%, and 96% respectively.

SCIENCE (2022)

Add to Collection

Article Immunology

Determinants of Immune Response to Anti-SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Prospective Cohort Study

Maria Magicova et al.

Summary: The immune response to SARS-CoV-2 vaccination is impaired in kidney transplant recipients, especially in those who are SARS-CoV-2-naive. Factors such as mycophenolate use and prior depleting therapy contribute to the impaired humoral response. Survivors of COVID-19 and those vaccinated on the waiting list prior to transplantation exhibit a robust immune response to mRNA vaccines.

TRANSPLANTATION (2022)

Add to Collection

Editorial Material Immunology

Simple Vaccination Is not Enough for the Transplant Recipient

Jeremy R. Chapman et al.

TRANSPLANTATION (2022)

Add to Collection

Article Immunology

Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients

Chris J. Callaghan et al.

Summary: The study in England found that vaccination of SOT recipients against SARS-CoV-2 can reduce infection-related mortality, with better outcomes seen in recipients of the ChAdOx1-S vaccine. However, overall protection remains inferior to that in the general population.

TRANSPLANTATION (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Covid-19: What do we know about omicron sublineages?

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2022)

Add to Collection

Article Transplantation

Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients

Olivier Marion et al.

Summary: This retrospective study aimed to identify predictive factors for humoral response to SARS-CoV-2 vaccine in solid organ transplant (SOT) patients. The study found that male gender, a longer period between transplantation and vaccination, liver transplant recipients, a higher lymphocyte count at baseline, a higher estimated glomerular filtration rate, and receiving certain drug combinations were independent predictive factors for a better humoral response to the vaccine. Conversely, younger patients, thoracic organ recipients, induction therapy recipients, and patients receiving certain drug combinations had a lower humoral response to the vaccine.

TRANSPLANTATION DIRECT (2022)

Add to Collection

Article Transplantation

Risk Factors Associated With an Impaired Antibody Response in Kidney Transplant Recipients Following 2 Doses of the SARS-CoV-2 mRNA Vaccine

Stephanie G. Yi et al.

Summary: This study reports the observations of anti-SARS-CoV-2 antibody levels in kidney transplant recipients after receiving the SARS-CoV-2 mRNA vaccine. The study found a low antibody response rate in kidney transplant recipients, which may be associated with their immunosuppressive state. Further research is needed to evaluate whether higher vaccine doses or additional booster doses are necessary for kidney transplant recipients.

TRANSPLANTATION DIRECT (2022)

Add to Collection

Letter Surgery

Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients

Arnaud Del Bello et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Surgery

Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients

Marta Kantauskaite et al.

Summary: Kidney transplant recipients (KTRs) have a weaker immune response to SARS-CoV-2 vaccination compared to controls, with mycophenolate mofetil (MMF) treatment being the strongest predictor for impaired response. Adjusting MMF dose may improve the immune response in KTRs.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Surgery

Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients

Louise Benning et al.

Summary: Seroconversion after COVID-19 vaccination is compromised in kidney transplant recipients, and emerging variants pose an increasing threat to these patients. Following a third vaccine dose, neutralizing antibodies in kidney transplant recipients are significantly lower compared to healthy controls, with reduced efficacy against the B.1.1.529 (omicron) variant.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Surgery

Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era

Allan B. Massie et al.

Summary: Estimating the mortality burden of COVID-19 on solid organ transplant recipients is crucial for understanding the impact of the disease. A study found that COVID-19 likely caused over 5000 excess deaths among SOTRs, representing 1 in 75 SOTRs and a substantial proportion of all deaths among SOTRs during the study period.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Letter Urology & Nephrology

Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients

Ayman Al Jurdi et al.

KIDNEY INTERNATIONAL (2022)

Add to Collection

Letter Infectious Diseases

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3

Prerna Arora et al.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Letter Medicine, General & Internal

Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers

Sarang K. Yoon et al.

Summary: In a group of frontline healthcare workers, a third dose of an mRNA vaccine provided 91% protection against SARS-CoV-2 infection with the delta variant and 60% protection against the omicron variant.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Immunology

Real-world Impact of 2-dose SARS-CoV-2 Vaccination in Kidney Transplant Recipients

Caitriona M. McEvoy et al.

TRANSPLANTATION (2022)

Add to Collection

Article Immunology

A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response

Andrew H. Karaba et al.

Summary: Humoral responses to COVID-19 vaccines are attenuated in solid organ transplant recipients. Additional vaccine doses can increase neutralizing capacity against multiple variants of concern, but the neutralization effect against the Omicron variant is poor.

TRANSPLANTATION (2022)

Add to Collection

News Item Medicine, General & Internal

Covid-19: Evusheld is approved in UK for prophylaxis in immunocompromised people

Jacqui Wise

BMJ-BRITISH MEDICAL JOURNAL (2022)

Add to Collection

Article Medicine, Research & Experimental

Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases

Roya M. Dayam et al.

Summary: Limited information is available on the impact of immunosuppressants on COVID-19 vaccination in patients with immune-mediated inflammatory diseases. This observational cohort study investigated the immunogenicity of SARS-CoV-2 mRNA vaccines in adult patients with various inflammatory diseases. The study found that antibody and T cell responses to SARS-CoV-2 were lower in patients with immune-mediated inflammatory diseases compared to healthy controls, especially those treated with anti-TNF therapy. The findings support the administration of a third dose of the mRNA vaccine and continuous monitoring of immunity in these patient groups.

JCI INSIGHT (2022)

Add to Collection

News Item Multidisciplinary Sciences

WHAT THE LATEST OMICRON SUBVARIANTS MEAN FOR THE PANDEMIC

Ewen Callaway

NATURE (2022)

Add to Collection

Article Immunology

A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination

Karen Colwill et al.

Summary: This study describes a scalable solution to detect and quantify SARS-CoV-2 antibodies, discriminate between natural infection and vaccination-induced responses, and assess the inhibitory effect of antibodies on ACE2-spike interaction. They developed methods and reagents for antibody detection using ELISA and snELISA, enabling large-scale analysis. In addition, they provided detailed protocols for the experiments.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2022)

Add to Collection

Article Surgery

Is COVID-19 infection more severe in kidney transplant recipients?

Sophie Caillard et al.

Summary: Transplant recipients had a higher COVID-19-related mortality compared to nontransplant hospitalized patients but did not differ significantly in the rate of severe disease. Factors associated with severe COVID-19 included age, cardiovascular disease, dyspnea, fever, lymphopenia, and CRP.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Review Multidisciplinary Sciences

T cell response to SARS-CoV-2 infection in humans: A systematic review

Madhumita Shrotri et al.

Summary: The study found that COVID-19 patients exhibit T cell lymphopenia, which is positively correlated with disease severity, duration of RNA positivity, and non-survival. Those with severe or critical disease tend to develop more robust, virus-specific T cell responses. Cross-reactive T cell responses have been demonstrated in unexposed and uninfected adults, but their significance for protection and susceptibility remains unclear.

PLOS ONE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Shuo Feng et al.

Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

Ronen Arbel et al.

Summary: Among 843,208 participants in Israel aged 50 years or older who had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster during the 54-day study period.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Urology & Nephrology

Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients

Demetra Tsapepas et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Letter Medicine, General & Internal

Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant

Nassim Kamar et al.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

William A. Werbel et al.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Third Time's a Charm - Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients

Winfred W. Williams et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Nassim Kamar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Moriah Bergwerk et al.

Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Immunology

Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients

Caroline X. Qin et al.

TRANSPLANTATION (2021)

Add to Collection

Editorial Material Immunology

Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Jennifer L. Alejo et al.

TRANSPLANTATION (2021)

Add to Collection

Article Immunology

Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients

Hector Rincon-Arevalo et al.

Summary: Patients with kidney failure are at increased risk for SARS-CoV-2 infection, making effective vaccination critical. However, studies have found significantly impaired antibody responses to the BNT162b2 vaccine in kidney transplant recipients and dialysis patients, leading to insufficient immune responses.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

Arne Sattler et al.

Summary: The study analyzed immune responses in kidney transplant recipients after receiving the BNT162b2 vaccine, finding weaker antibody responses in transplant patients compared to healthy individuals and most hemodialysis patients. Additionally, spike-specific T cell responses were significantly reduced in transplant patients, indicating a need for revised vaccination strategies in immunosuppressed individuals.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Urology & Nephrology

Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation

Karen M. Krueger et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Luca Piccoli et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Factors associated with COVID-19-related death using OpenSAFELY

Elizabeth J. Williamson et al.

NATURE (2020)

Add to Collection

Article Medicine, Research & Experimental

A simple protein-based surrogate neutralization assay for SARS-CoV-2

Kento T. Abe et al.

JCI INSIGHT (2020)

Add to Collection

Article Transplantation

COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

Luuk B. Hilbrands et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)

Add to Collection

Article Immunology

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Jianhui Nie et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.